Sign up Australia
Proactive Investors - Run By Investors For Investors

Admedus secures $6 million to expand medical technologies strategy

The placement to institutional and sophisticated investors will be followed by a share purchase plan for existing shareholders.
Laboratory tests
The company is accelerating the commercialisation of new products

Admedus Ltd (ASX:AHZ) has raised about $6 million after securing commitments from institutional and sophisticated investors in a placement at 30 cents per share.

The medical technologies company has also invited existing shareholders to participate in a share purchase plan (SPP).

This offers the opportunity to subscribe for up to $15,000 worth of new Admedus shares at an issue price of 30 cents per share.

READ: Admedus has healthy mix of reliable Infusion earnings and strong revenue growth from ADAPT

Funds raised will enable the company to expand and progress its strategic projects, including the acceleration of its 3D product portfolio from development to commercialisation.

CEO Wayne Paterson said: “The capital raising follows growing interest from sophisticated institutional investors who value Admedus as an exciting and credible investment opportunity recognising the potential of our unique product portfolio.”

Business transformation

Admedus has undergone a dramatic transformation and experienced unprecedented levels of growth during the past 18 months.

The company has delivered record sales and revenue growth across its ADAPT and infusion product lines, and has restructured key business units.

Entry into emerging markets

It has also secured entry into significant emerging markets and expanded product offerings with the introduction of the ground-breaking 3D shaped tissue franchise.

 

 

Paterson said: “Since the implementation of our new strategy, the company has worked diligently across all areas to improve efficiencies, reduce expenses and elevate the reputation and credibility of the business within the global medtech sector.”

Admedus recently submitted multiple IP applications in the US as it targets entry into the lucrative TAVR market, currently worth US$3.5 billion and expected to grow to US$5 billion by 2020.

READ: Admedus appoints medtech expert Michael Oswell as vice president, development

“We are only just beginning to explore the full potential of our unique shaped tissue technology with 16 potential new products in the pipeline, each one leveraging the benefits of our clinically-superior ADAPT technology,” Paterson said.

“Momentum continues to build across the business with recent announcements including the appointment of a new VP - Development, applications for additional product patents and the signing of a letter of intent to provide alternative funding for our immunotherapies division.”

View full AHZ profile View Profile

Admedus Ltd Timeline

Related Articles

blood
April 01 2018
The company is in the process of raising £5mln, with a possible further £1mln through a share issue at 52.5p
newspaper with word cancer magnified
January 15 2018
"In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently
Summit
January 26 2018
Interim results for a study on ezutromid revealed a “statistically significant and meaningful” reduction in muscle damage, the company said

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use